LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Начало・Списък с акции・Krystal Biotech Inc

Krystal Biotech Inc

Затворен

СекторЗдравеопазване

243.77 -0.93

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

242.78

Максимум

245.72

Ключови измерители
By Trading Economics
Приходи	41M 79M
Продажби	1.8M 98M
P/E Средно за сектора	35.09 77.671
Марж на печалбата	81.15
Служители	275
EBITDA	10M 50M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	-9.36% downside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.3B 6.8B
Предишно отваряне	244.7
Предишно затваряне	243.77

Настроения в новините

By Acuity

50%

158 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

133.221 / 169.73 Подкрепа & съпротива

Krystal Biotech Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.12.2025 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13.12.2025 г., 00:04 ч. UTC

Придобивния, сливания и поглъщания

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14.12.2025 г., 23:46 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14.12.2025 г., 23:36 ч. UTC

Пазарно говорене

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14.12.2025 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Fortescue to Take Full Control of US$101M Copper Miner Alta

14.12.2025 г., 22:02 ч. UTC

Придобивния, сливания и поглъщания

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14.12.2025 г., 22:01 ч. UTC

Придобивния, сливания и поглъщания

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14.12.2025 г., 22:01 ч. UTC

Придобивния, сливания и поглъщания

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14.12.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14.12.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14.12.2025 г., 21:59 ч. UTC

Придобивния, сливания и поглъщания

Fortescue to Acquire Remaining 64% of Alta Copper

14.12.2025 г., 17:00 ч. UTC

Печалби

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14.12.2025 г., 08:30 ч. UTC

Придобивния, сливания и поглъщания

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13.12.2025 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13.12.2025 г., 08:00 ч. UTC

Придобивния, сливания и поглъщания

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13.12.2025 г., 07:00 ч. UTC

Придобивния, сливания и поглъщания

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13.12.2025 г., 00:24 ч. UTC

Придобивния, сливания и поглъщания

Want a Piece Of SpaceX? -- Barrons.com

12.12.2025 г., 23:49 ч. UTC

Придобивния, сливания и поглъщания

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12.12.2025 г., 22:52 ч. UTC

Пазарно говорене

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12.12.2025 г., 22:32 ч. UTC

Печалби

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.12.2025 г., 20:45 ч. UTC

Печалби

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12.12.2025 г., 20:41 ч. UTC

Пазарно говорене

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12.12.2025 г., 20:20 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12.12.2025 г., 19:23 ч. UTC

Печалби

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12.12.2025 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12.12.2025 г., 18:33 ч. UTC

Придобивния, сливания и поглъщания

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12.12.2025 г., 18:31 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12.12.2025 г., 17:49 ч. UTC

Печалби

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12.12.2025 г., 17:34 ч. UTC

Придобивния, сливания и поглъщания

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Сравнение с други в отрасъла

Ценова промяна

Krystal Biotech Inc Прогноза

Ценова цел

By TipRanks

-9.36% надолу

12-месечна прогноза

Среден 221.75 USD -9.36%

Висок 255 USD

Нисък 198 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Krystal Biotech Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

9 ratings

Купи

Задържане

Продай

Според 9 анализатори, дали борсови рейтинги на Krystal Biotech Inc през последните 3 месеца.

Техническа оценка

By Trading Central

133.221 / 169.73Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Настроение

By Acuity

158 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.